Founded in West Lafayette, United States, Novilytic is a molecular recognition company dedicated to ensuring the quality of lifesaving medicines through advanced nanotechnology. Their core mission is to enhance drug safety and efficacy by providing precise molecular structure analysis. Novilytic's flagship product, the Proteometer-L Kit, identifies and quantifies titer and relative aggregate content in pharmaceuticals, targeting the biopharmaceutical market.
Notable figures associated with Novilytic include experts in nanotechnology and pharmaceutical sciences. The company has garnered attention from key investors in the biotech sector. Among its key achievements is the development of the Proteometer® technology, which significantly expedites molecular structure analysis. Novilytic's impact lies in its contribution to improving drug quality control, thereby enhancing patient safety and treatment outcomes.
